Vitiligo News

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Certain racial groups continue to be underrepresented in vitiligo clinical trials, according to a study.

While the art of tattooing has been present for centuries, the medical implications are only recently coming to light with modern medicine.

Healio has compiled June’s most-read news in dermatology.

Makeup not only has cosmetic applications, but medical ones too.

Incyte has launched the Vitiligo Innovators Program to honor exceptional individuals who have made significant contributions to the vitiligo community, according to a company press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

The first subject has been dosed in a phase 2b trial evaluating VYN201 for the treatment of active or stable nonsegmental vitiligo.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

Healio has compiled April’s most-read news in dermatology.